Inflammatory and bone turnover markers in a cross-sectional and prospective study of acute Charcot osteoarthropathy

Diabetic Medicine

Volumn 32, Issue 2, 2015, Pages 267-273

  Petrova, N L ^a   Dew, T K ^a   Musto, R L ^a   Sherwood, R A ^a   Bates, M ^a   Moniz, C F ^a   Edmonds, M E ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; INTERLEUKIN 1BETA; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; IL6 PROTEIN, HUMAN; PEPTIDE;

ADULT; AGED; ARTICLE; BONE TURNOVER; CAST APPLICATION; CHARCOT OSTEOARTHROPATHY; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROPATHIC JOINT DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHROPATHY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TREATMENT DURATION; ARTHROPATHY, NEUROGENIC; BLOOD; COHORT ANALYSIS; COMPLICATION; DOWN REGULATION; ETIOLOGY; IMMOBILIZATION; LONGITUDINAL STUDY; OSTEOLYSIS; PATHOPHYSIOLOGY; PREVENTION AND CONTROL; REMISSION; UPREGULATION;

ADULT; AGED; ARTHROPATHY, NEUROGENIC; BIOLOGICAL MARKERS; BONE RESORPTION; COHORT STUDIES; COLLAGEN TYPE I; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOWN-REGULATION; HUMANS; IMMOBILIZATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LONGITUDINAL STUDIES; MIDDLE AGED; PEPTIDES; PROSPECTIVE STUDIES; REMISSION INDUCTION; UP-REGULATION;

EID: 84921341363     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12590     Document Type: Article

References (26)

1. Jeffcoate WJ, Game F, Cavanagh PR. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 2005; 366: 2058-2061.
2. Gough A, Abraha H, Li F, Purewal TS, Foster AV, Watkins PJ et al. Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic diabetic Charcot neuroarthropathy. Diabet Med 1997; 14: 527-531.
3. Piaggesi A, Rizzo L, Golia F, Costi D, Baccetti F, Ciaccio S et al. Biochemical and ultrasound tests for early diagnosis of active neuro-osteoarthropathy (NOA) of the diabetic foot. Diabetes Res Clin Pract 2002; 58: 1-9.
4. Petrova NL, Moniz C, Elias DA, Buxton-Thomas M, Bates M, Edmonds ME. Is there a systemic inflammatory response in the acute charcot foot? Diabetes Care 2007; 30: 997-998.
5. Uccioli L, Sinistro A, Almerighi C, Ciaprini C, Cavazza A, Giurato L et al. Proinflammatory modulation of the surface and cytokine phenotype of monocytes in patients with acute Charcot foot. Diabetes Care 2010; 33: 350-355.
6. Petrova NL, Edmonds ME. A prospective study of calcaneal bone mineral density in acute Charcot osteoarthropathy. Diabetes Care 2010; 33: 2254-2256.
7. Rogers LC, Frykberg RG, Armstrong DG, Boulton AJ, Edmonds M, Van GH et al. The Charcot foot in diabetes. Diabetes Care 2011; 34: 2123-2129.
8. Petrova NL, Edmonds ME. Charcot neuro-osteoarthropathy-current standards. Diabetes Metab Res Rev 2008; 24(Suppl 1): S58-61.
9. Hansson P, Lindblom U, Lindstrom P. Graded assessment and classification of impaired temperature sensibility in patients with diabetic polyneuropathy. J Neurol Neurosurg Psychiatry 1991; 54: 527-530.
10. Petrova NL, Foster AVM, Edmonds ME. Calcaneal bone mineral density in patients with Charcot neuropathic osteoarthropathy: differences between Type 1 and Type 2 diabetes. Diabet Med 2005; 22: 756-761.
11. Young MJ, Breddy JL, Veves A, Boulton AJ. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds A prospective study. Diabetes Care 1994; 17: 557-560.
12. Michail M, Jude E, Liaskos C, Karamagiolis S, Makrilakis K, Dimitroulis D et al. The performance of serum inflammatory markers for the diagnosis and follow-up of patients with osteomyelitis. Int J Low Extrem Wounds 2013; 12: 94-99.
13. Giganti MG, Liuni F, Celi M, Gasbarra E, Zenobi R, Tresoldi I et al. Changes in serum levels of TNF-alpha, IL-6, osteoprotegerin, RANKL and their correlation with radiographic and clinical assessment in fragility fractures and high energy fractures. J Biol Regul Homeost Agents; 26: 671-680.
14. Rasul S, Ilhan A, Wagner L, Luger A, Kautzky-Willer A. Diabetic polyneuropathy relates to bone metabolism and markers of bone turnover in elderly patients with type 2 diabetes: greater effects in male patients. Gend Med 2012; 9: 187-196.
15. Elefteriou F. Regulation of bone remodeling by the central and peripheral nervous system. Arch Biochem Biophys 2008; 473: 231-236.
16. Nyazee HA, Finney KM, Sarikonda M, Towler DA, Johnson JE, Babcock HM. Diabetic foot osteomyelitis: bone markers and treatment outcomes. Diabetes Res Clin Pract 2012; 97: 411-417.
17. Ivaska KK, Gerdhem P, Akesson K, Garnero P, Obrant KJ. Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res; 22: 1155-1164.
18. Pearson R G S, Divyateja H, Seagrave M, Game FL, Jeffcoate WJ et al. Charcot neuropathic osteoarthropathy, proinflammatoty cytokines and bone turnover markers. Abstract. J Bone Joint Surg Br 2012; 95-B.
19. Mabilleau G, Petrova NL, Edmonds ME, Sabokbar A. Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia 2008; 51: 1035-1040.
20. Ndip A, Williams A, Jude EB, Serracino-Inglott F, Richardson S, Smyth JV et al. The RANKL/RANK/osteoprotegerin signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy. Diabetes 2011; 60: 2187-2196.
21. Nybo M, Poulsen MK, Grauslund J, Henriksen JE, Rasmussen LM. Plasma osteoprotegerin concentrations in peripheral sensory neuropathy in Type 1 and Type 2 diabetic patients. Diabet Med 2010; 27: 289-294.
22. Petrova NL, Shanahan CM. Neuropathy and the vascular-bone axis in diabetes: lessons from Charcot osteoarthropathy. Osteoporos Int 2014; 25: 1197-1207.
23. Petrova NL, Shanahan C, Edmonds M. The proinflammatory cytokines TNF-a and IL-6 modulate RANKL-mediated osteoclastic resorption in vitro in patients with acute Charcot osteoarthropathy. Abstract. Diabetologia 2011; 54(Suppl 1):S11.
24. Baumhauer JF, O'Keefe RJ, Schon LC, Pinzur MS. Cytokine-induced osteoclastic bone resorption in charcot arthropathy: an immunohistochemical study. Foot Ankle Int 2006; 27: 797-800.
25. Aragón-Sánchez J, Lázaro-Martínez JL, Cabrera-Galván JJ. Additional information on the role of histopathology in diagnosing diabetic foot osteomyelitis. Diabet Med 2013; 31: 113-116.
26. Divyateja H, Shu KSS, Pearson RG, Scammell BE, Game FL, Jeffcoate WJ. Local and systemic concentrations of pro-inflammatory cytokines, osteoprotegerin, sRANKL and bone turnover markers in acute Charcot foot and in controls. Abstract. Diabetologia 2011; 54(Suppl 1): S11-S12.